| 13.22 0.31 (2.4%) | 09-14 12:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.04 | 1-year : | 18.36 |
| Resists | First : | 14.59 | Second : | 15.72 |
| Pivot price | 14  |
|||
| Supports | First : | 12.77 | Second : | 10.62 |
| MAs | MA(5) : | 13.25 |
MA(20) : | 14.19 |
| MA(100) : | 13.9 |
MA(250) : | 12.61 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 7.7 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 26.95 | Low : | 5.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CRVS ] has closed above bottom band by 14.6%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.58 - 13.71 | 13.71 - 13.79 |
| Low: | 12.5 - 12.67 | 12.67 - 12.77 |
| Close: | 12.72 - 12.99 | 12.99 - 13.15 |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Thu, 03 Sep 2026
A biotech company's live healthcare talk is set for Sept. 10. Its webcast stays online 90 days. - Stock Titan
Thu, 27 Aug 2026
Corvus lymphoma study: 67% were alive at 24 months after 1-3 prior therapies - Stock Titan
Thu, 27 Aug 2026
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment - Seeking Alpha
Sat, 22 Aug 2026
Corvus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRVS - TradingView
Mon, 17 Aug 2026
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 84 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 86.2 (%) |
| Shares Short | 19,130 (K) |
| Shares Short P.Month | 18,060 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.7 % |
| Return on Equity (ttm) | -35.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -20.54 |
| PEG Ratio | 0 |
| Price to Book value | 4.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -24.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|